Statistics for Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study
Total visits
| views | |
|---|---|
| Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study | 278 |
Total visits per month
| views | |
|---|---|
| November 2024 | 0 |
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 0 |
| April 2025 | 0 |
| May 2025 | 0 |
File Visits
| views | |
|---|---|
| qai-71-0530.pdf | 213 |
| java.util.UUID:4648c339-3672-409e-bc77-0b4508673dc0 | 43 |
| java.util.UUID:8e199dbb-6214-4ca8-a927-78a920d24ab7 | 8 |
Top country views
| views | |
|---|---|
| United States | 186 |
| Germany | 21 |
| China | 9 |
| United Kingdom | 6 |
| Ukraine | 6 |
| Sweden | 5 |
| Russia | 4 |
| Canada | 2 |
| France | 2 |
| India | 1 |
| Iran | 1 |
| Italy | 1 |
| Japan | 1 |
| South Korea | 1 |
| Kazakhstan | 1 |
| Malaysia | 1 |
| Thailand | 1 |
Top city views
| views | |
|---|---|
| Wilmington | 56 |
| Ann Arbor | 33 |
| Kiez | 14 |
| Houston | 13 |
| Cambridge | 12 |
| White Plains | 12 |
| Fairfield | 10 |
| Jacksonville | 7 |
| Beijing | 6 |
| Kiev | 5 |
| Stockholm | 5 |
| Washington | 5 |
| Gunzenhausen | 3 |
| Overland Park | 3 |
| Saint Petersburg | 3 |
| San Francisco | 3 |
| Endingen | 2 |
| London | 2 |
| Roubaix | 2 |
| Shanghai | 2 |
| Toronto | 2 |
| Alexandria | 1 |
| Almaty | 1 |
| Bangkok | 1 |
| Brooklyn | 1 |
| Buffalo | 1 |
| Cedar Rapids | 1 |
| Daegu | 1 |
| Darrous | 1 |
| Gainesville | 1 |
| Indianapolis | 1 |
| Kharkov | 1 |
| Lake Mary | 1 |
| Milan | 1 |
| Moscow | 1 |
| Munich | 1 |
| New York | 1 |
| Nürnberg | 1 |
| Philadelphia | 1 |
| Provo | 1 |
| Scottsdale | 1 |
| Seattle | 1 |
| Seremban | 1 |
| Shenzhen | 1 |
| Warrington | 1 |